18.17USD-0.68%Mkt Cap: 1.15B USDP/E: —Last update: 2026-06-01
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclona…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.15B USD
Enterprise Value711.28M USD
Revenue (TTM)0 USD
Gross Profit-193.59M USD
Net Income (TTM)-377.74M USD
Revenue/Share0.0000 USD
Last Price18.17 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees167
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.12
PEG—
EV/EBITDA-2.83
EV/Revenue—
P/SInfinity
P/B4.14
EPS (TTM)-9.10
EPS (Forward)-2.27
52W Range
8.91026% of range44.60
52W High44.60 USD
52W Low8.910 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-3777.37%
ROE-156.00%
ROA-98.46%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-172.33M USD
CapEx (TTM)35.02M USD
FCF Margin—
FCF Yield-14.48%
Net Debt-450.38M USD
Net Debt/EBITDA1.79
Balance Sheet
Debt/Equity0.01
Current Ratio11.94
Quick Ratio11.74
Book Value/Sh4.444 USD
Cash/Share11.36 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)42.13 USD
Target Range22.00 USD – 55.00 USD
# Analysts8
Ownership
Shares Out.63.13M
Float39.68M
Insiders23.20%
Institutions90.42%
Short Interest
Short Ratio21.9d
Short % Float25.23%
Short % Out.16.93%
Shares Short10.69M
Short (prev mo.)10.22M
Technical
SMA 5020.01 (-9.2%)
SMA 20024.58 (-26.1%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)489.04K
Avg Vol (10d)609.47K
Technical Indicators
RSI (14)44.8
MACD-0.4889
MACD Signal-0.5105
MACD Hist.+0.0215
BB Upper21.49 USD
BB Middle19.26 USD
BB Lower17.04 USD
BB Width23.09%
ATR (14)1.342 USD
Vol Ratio (20d)0.43x